CRT-200.39 Comparisons of Two Different Platelet Glycoprotein IIb/IIIa Receptor Blockers Clotinab™ and ReoPro® in Patients With Acute Myocardial Infarction

Reopro® (abciximab) is the Fab fragment of the chimeric human monoclonal antibody 7E3. Clotinab™ (abciximab) was produced by inserting anti-platelet glycoprotein (GP) IIb/IIIa DNA into a Chinese hamster’s ovary cell and is expected to have same efficacy with Reopro®. Although the increasing